News | August 21, 2023
Venus Remedies launches its flagship R&D drug Elores in Oman
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Take proper precautions and seek timely treatment!
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Currently there are no vaccines approved anywhere in the world for gonorrhoea, and antimicrobial resistance to existing treatments is increasing
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
